Latest:
Incorporating ctDNA Into Routine Practice: Clinical Pearls
Advice to GI oncologists in the community on using ctDNA testing to detect minimal residual disease and inform treatment decisions in colorectal cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Janine Joseph, MS, MBA
Janine Joseph, MS, MBA, is a senior research specialist at Roswell Park Comprehensive Cancer Center.
Latest:
Joseph on the Research Behind the Role of Exercise and Supportive Care in Myeloma
Janine Joseph, MS, MBA, discusses the current state of research and future directions for resistance training interventions in patients with multiple myeloma.
Yago L. Nieto, MD, PhD
Latest:
Dr. Nieto on High-Dose Chemotherapy and ASCT in R/R Multiple Myeloma
Yago L. Nieto, MD, PhD, professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses findings from a phase 2 trial investigating panobinostat (Farydak), gemcitabine, busulfan, and melphalan plus autologous stem cell transplant (ASCT) in patients with high-risk or relapsed/refractory multiple myeloma.
Selina M. Luger, MD, FRCPC
Latest:
Women in Oncology: Prioritization and Passionate Legacies
Selina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.
Nina D'Abreo, MD,
Latest:
Dr D'Abreo on Patient Consideration When Choosing Treatments in HER2+ Breast Cancer
Nina D'Abreo, MD, discusses the importance of considering a patient’s medical history and preferences when deciding on a treatment course in HER2-positive breast cancer and highlights the important role of surgeons within breast cancer treatment.
Anil Parwani, MD, PhD, MBA
Latest:
Final Reflections: Key Takeaways and Future Opportunities With QCS and TROP2 NMR
Panelists discuss the introduction of quantitative cell scoring (QCS) for TROP2 as a significant artificial intelligence (AI)-driven advancement in oncology, emphasizing its ability to provide precise, quantitative biomarker assessment that complements molecular data like EGFR status. The panelists also highlight the importance of pathologists embracing digital pathology tools to enhance diagnostic accuracy and treatment planning while recognizing the technology’s early but promising role in expanding patient identification for targeted therapies and its potential broader impact on precision oncology.
Aydah Alawadhi, MBBS
Aydah Alawadhi, MBBS, is a consultant medical oncologist and chair of the Haematology & Oncology Division at Sheikh Shakhbout Medical City.
Latest:
Dr Alawadhi on the Link Between Obesity/Overweight and Breast Cancer Outcomes
Aydah Alawadhi, MBBS, discusses the effect of obesity and overweight status on patient outcomes across subgroups of early-stage breast cancer.
Elizabeth Wulff-Burchfield, MD
Latest:
Postimmunotherapy Options in RCC: Latest Trial Data and Expert Perspectives on Rechallenge Strategies
Experts discuss key findings from the phase 3 CONTACT-03 trial investigating atezolizumab plus cabozantinib vs cabozantinib alone in inoperable advanced renal cell carcinoma (aRCC) after immune checkpoint inhibitor (ICI) treatment, along with insights from real-world data on sequencing strategies and the efficacy of tyrosine kinase inhibitors (TKIs) after prior ICI therapy.
Hyein Jeon, MD
Hyein Jeon, MD, is a hematology oncology fellow at Albert Einstein College of Medicine and Montefiore Medical Center
Latest:
Dr Jeon on Research Presented at an OncLive Lung Cancer Fellows Forum
Hyein Jeon, MD, highlights key abstracts and takeaways from an OncLive Fellows Forum on lung cancer.
Julie E. Chang, MD
Latest:
COVID-19 Pandemic Highlights Underrecognized Vulnerability of Patients With CLL
At the onset of the pandemic, hematology/oncology physicians were challenged in counseling patients with serious underlying malignant conditions about their risk for severe disease due to COVID-19.